■肝内胆管癌(iCCA)通常是一种致命的恶性肿瘤,在全球范围内发病率上升。手术切除目前仍然是唯一的治愈性治疗。然而,因为只有少数iCCA适合切除,需要新的治疗方式。我们的目的是对现有的关于iCCA使用消融疗法的文献进行系统回顾和荟萃分析,并通过计算合并的生存结果来评估其作为治疗方式的疗效,并研究预后因素与生存之间的关系。
■对PubMed数据库进行了相关文章的全面搜索。包括评估接受消融的iCCA患者生存率的研究。提取了患者的数据,肿瘤和治疗特征和存活率。随机效应荟萃分析用于汇总数据。使用Galbraith图研究异质性;使用基于回归的荟萃分析制定气泡图。
■共有10项研究纳入最终分析,共产生206名患者(69.5%为男性,中位年龄:51.2-72.5)和320个肿瘤。在所有患者中,70.4%为iCCA复发病例,原发性iCCA占29.6%。中位总生存期为8.7至52.4个月。汇集1-,3年和5年生存率为76%(95%置信区间:68-83%),33%(21-44%)和16%(7-26%),分别。中位年龄之间没有发现显着关联,肿瘤数量或中位肿瘤大小和1年生存率。
■消融疗法作为iCCA的治疗方式显示出有希望的潜力。然而,需要进一步的研究来验证这些发现。
UNASSIGNED: Intrahepatic cholangiocarcinoma (iCCA) is usually a fatal malignancy with rising incidence globally. Surgical resection currently remains the only curative treatment. However, as only a minority of iCCA is amenable to resection, new therapeutic modalities are needed. Our aims were to systematically review and perform a meta-analysis on the existing literature regarding the use of ablative therapies for iCCA and to assess their efficacy as a treatment modality by calculating pooled survival results and investigate associations between prognostic factors and survival.
UNASSIGNED: A comprehensive search of the PubMed database for relevant articles was performed. Studies assessing survival in patients with iCCA undergoing ablation were included. Data were extracted on patient, tumour and treatment characteristics and survival. Random effects meta-analysis was used to pool the data. Galbraith plots were used to investigate heterogeneity; bubble plots were formulated using regression-based meta-analysis.
UNASSIGNED: A total of 10 studies were included in the final analysis, yielding an aggregate of 206 patients (69.5% males, median age: 51.2-72.5) and 320 tumours. Of all patients, 70.4% were recurrent cases of iCCA, and 29.6% were cases of primary iCCA. The median overall survival ranged from 8.7 to 52.4 months. Pooled 1-, 3- and 5-year survival rates were 76% (95% confidence interval: 68-83%), 33% (21-44%) and 16% (7-26%), respectively. No significant association was found between the median age, number of tumours or median tumour size and 1-year survival.
UNASSIGNED: Ablative therapies display promising potential as treatment modalities for iCCA. However, further research is necessary to validate these findings.